Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Guangdong Association of Clinical Trials
Novartis
Novartis
Pfizer
AstraZeneca
Shanghai Pulmonary Hospital, Shanghai, China
Institut Paoli-Calmettes
Fujian Cancer Hospital
Pfizer
Groupe Francais De Pneumo-Cancerologie
AstraZeneca
Merck Sharp & Dohme LLC